N/A N=8 Safety and Efficacy of Trastuzumab BS
Gastric Cancer
Primary: The Incidence of Adverse Drug Reactions (ADRs) — 4; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=294 Efficacy Study in Patients With Acne Vulgaris.
Acne Vulgaris
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 3 N=475 Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate — 138; 143 Participants
Phase 2 N=206 Efficacy and Safety Study of E2007 in Migraine Prophylaxis
Migraine Prophylaxis
Primary: Change From Baseline in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF) — -2.94; -2.73; -3.31; -3.00 Migraine period
Phase 3 N=327 Pediatric Schizophrenia Efficacy and Safety Study
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6. — 94.5; 94.0; 92.8; -18.6 units on a scale — p=0.0003
Phase 2 N=32 Efficacy and Safety of Itolizumab in COVID-19 Complications
Acute Respiratory Distress Syndrome · Cytokine Release Syndrome · Covid19
Primary: One-month Mortality Rate Between the Two Arms — 0; 3 participants
Phase 3 N=589 Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
Diabetes, Type I
Primary: Compare the Mean Change From Baseline to Week 52 in HbA1c — -0.13; -0.37 Percentage
N/A N=1,349 Efficacy and Tolerability of Xalatan in Patients
Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure
Phase 3 N=267 The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Pulmonary Hypertension
Primary: Categorized Change From Baseline in 6-Minute Walking Distance — 27; 46; 20; 26 participants
Phase 2 N=222 Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Change in Total Nasal Symptom Score From Baseline to Day 14. — -2.70; -4.05; -4.72; -4.05 units on a scale
Phase 3 N=396 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Schizophrenia
Primary: Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — 88.3; 88.1; -15.3; -13.4 score on a scale — p=0.0940
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 4 N=1,423 The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Absolute Change From Baseline in Haemoglobin A1c (HbA1c) — -1.19; -1.59; -1.61 (%)
Phase 3 N=511 Efficacy and Safety of Different Doses of Indacaterol
Asthma
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment — 2.50; 2.52; 2.59; 2.54 Liters
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
Phase 3 N=388 Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
Schizophrenia
Primary: Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42 — -33.4; -35.9 scores on a scale
Phase 2 N=64 Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
Relapsing Multiple Sclerosis
Primary: Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Core Part — 0.0670; 1.0413 lesions per scan — p=<0.001
Phase 2 N=391 Efficacy and Safety Study of SUNPG1623
Active Psoriatic Arthritis
Primary: Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate — 0.7949; 0.7722; 0.7143; 0.7308 proportion of subjects — p=0.0001
Phase 3 N=446 Safety and Efficacy of Cariprazine in Schizophrenia
Schizophrenia
Primary: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score — -16.0; -22.8; -25.9 Units on a Scale — p=0.0029
Phase 2 N=143 Evaluate Safety, Efficacy and Pharmacokinetics
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
Phase 2 N=568 Efficacy and Safety of Bromfenac Ophthalmic Solution
Cataract Surgery
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 157; 164 Participant
Phase 3 N=325 Evaluation of Efficacy and Safety of SDN-037
Inflammation and Pain Associated With Ocular Surgery
Primary: Subjects With an Anterior Chamber Cell Grade of 0 at Day 15 — 96; 30 Participants — p=<.0001
Phase 3 N=1,134 Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of…
Phase 3 N=31 Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Dominant Dystrophic Epidermolysis Bullosa
Primary: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 — 20.9; 6.7 number of wounds with complete healing — p=0.00192
Phase 3 N=504 Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Treatment Failure — 184; 141 participants — p=<0.0001
Phase 3 N=253 Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
Partial Epilepsy
Primary: Seizure Frequency — 7.3; 5.7; 5.5 ln (Seizures) per 4 weeks
Phase 3 N=1,729 Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) — -0.030; 0.269; 0.213; 0.144 Liters — p=<0.0001
Phase 3 N=552 Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 2 + 1 Day, Day 15) — 1.35; 1.38; 1.38; 1.40 Liters
Phase 3 N=1,142 Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of…